Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vital KSK HoldingsTSE:3151 -0.68%63 3-Year EBITDA Growth Rate is 13.40% as of Mar. 2026, which is 87% above its 10-year median of 7.15. GuruFocus rates TSE:3151 with a GF Score™ of 63/100 and a GF Value™ of 円1,333.65 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 107 Medical Distribution companies, Vital KSK Holdings ranks better than 65.42% on this metric.
During the past 12 months, Vital KSK Holdings's average EBITDA Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vital KSK Holdings was 212.70% per year. The lowest was -11.40% per year. And the median was 7.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vital KSK Holdings 3-Year EBITDA Growth Rate Related Terms
TSE:3151 vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Vital KSK Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vital KSK Holdings 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Vital KSK Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vital KSK Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.40% mean?
Vital KSK Holdings (TSE:3151) has a 3-Year EBITDA Growth Rate of 13.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vital KSK Holdings and its competitors. This is 87% above median its historical median of 7.15. According to the industry distribution chart, Vital KSK Holdings ranks #37 out of 107 companies in the Medical Distribution industry, placing it in the top 34.6%.
Is Vital KSK Holdings' 3-Year EBITDA Growth Rate too high?
Vital KSK Holdings' current 3-Year EBITDA Growth Rate of 13.40% is 87% above median its 10-year median of 7.15. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 6.10. Vital KSK Holdings' value of 13.40% is 119.7% above this industry median. Based on the distribution chart, Vital KSK Holdings ranks #37 out of 107 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Vital KSK Holdings has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vital KSK Holdings' 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Vital KSK Holdings ranks #37 out of 107 companies for 3-Year EBITDA Growth Rate. This puts Vital KSK Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.10. Vital KSK Holdings' value of 13.40% is 119.7% above this benchmark. While the company's 10-year median is 7.15 vs. the industry median of 6.10, Vital KSK Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.10, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vital KSK Holdings's current 3-Year EBITDA Growth Rate of 13.40% is 119.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vital KSK Holdings and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vital KSK Holdings's current 3-Year EBITDA Growth Rate is 13.40%, which is 87% above median its own 10-year median of 7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vital KSK Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vital KSK Holdings (TSE:3151) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,333.65, compared to a current price of 円1,608.00 — trading 20.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.40%, which is 87% above median its 10-year median of 7.15 and 119.7% above the Medical Distribution industry median of 6.10. Vital KSK Holdings' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vital KSK Holdings (TSE:3151), the current 3-Year EBITDA Growth Rate is 13.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vital KSK Holdings (TSE:3151) Overvalued in 2026?
Based on GuruFocus' analysis, Vital KSK Holdings stock appears to be overvalued.
The current stock price of 円1,608.00 is trading 20.6% above its estimated GF Value™ of 円1,333.65.
GuruFocus considers Vital KSK Holdings to be Modestly Overvalued.
Key valuation signals for TSE:3151:
3-Year EBITDA Growth Rate: 13.40% (87% above median its 10-year median of 7.15)
GF Value™: 円1,333.65 vs. price of 円1,608.00 (20.6% above fair value)
Industry Position: 119.7% above the Medical Distribution median (#37 of 107)
No single metric tells the full story. See the TSE:3151 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vital KSK Holdings Inc engaged in the wholesale and retail of pharmaceutical products. It operates through the Pharmaceutical Wholesale and Other segments. The Pharmaceutical Wholesale segment sells medicines, diagnostics, and medical devices to hospitals, medical institutions, and health practitioners. The Other segment includes retail of pharmaceutical products, wholesale of agrochemical and veterinary drugs, transportation, nursing care services, and medical consultancies. All the business activity of the group is primarily functioned through Japan and distributes its product within the Korean and to overseas market.
63GF Score
Get the complete analysis for TSE:3151
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3151 has been successfully added to your 
